Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute, Inc. (NASDAQ: TOI) generates a steady flow of news as it pursues its strategy in value-based community oncology care. Founded in 2007, the company describes itself as one of the largest value-based oncology groups in the United States, with over 180 employed and affiliate clinicians and more than 100 clinics and affiliate locations of care across five states. News about TOI often highlights how it combines specialized cancer care with value-based payment models and community-based delivery.
Investors and observers following TOI news can expect updates on financial performance, guidance, and outlook, including revenue mix across patient services, dispensary, and capitation arrangements. The company regularly issues press releases on quarterly results, non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow, and changes to its financial guidance. These items are often accompanied by management commentary on operational trends in areas like pharmacy, dispensary, and delegated contracts.
TOI’s news flow also covers clinical and operational initiatives. Examples include participation in CMS programs such as the Enhancing Oncology Model, where the company has reported Medicare savings and quality scores, as well as the launch of centers of excellence, such as a Lung Cancer Center of Excellence in Florida. Announcements may describe programs like its High Value Cancer Care initiative, 24/7 symptom management support, and efforts to reduce avoidable emergency department visits and admissions.
Another recurring theme in TOI news is technology and leadership. The company has reported partnerships to co-develop AI-enabled administrative automation, and it has announced leadership promotions and board changes that relate to technology strategy, people operations, and financial oversight. For readers tracking TOI, this news page offers a way to follow developments in value-based oncology care, operational efficiency initiatives, and governance updates over time.
The Oncology Institute (NASDAQ: TOI) announced an expanded partnership with McKesson Corporation focused on drug distribution and clinical technology. This multi-year agreement aims to streamline TOI’s pharmaceutical logistics and support its growth strategy. CEO Brad Hively emphasized the importance of this partnership for enhancing high-value oncology care delivery. Since 2007, TOI has been providing specialized cancer care, performing over 57,000 infusions and prescribing more than 8,000 chemotherapeutics annually.
CERRITOS, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group, announced CEO Brad Hively's participation in the 'Value-Based Care for Medicare' panel at the Cowen FutureHealth Conference on June 22 at 3:25 pm EST. Established in 2007, TOI provides specialized, evidence-based cancer care to around 1.5 million patients through over 50 clinics and 80+ employed clinicians, advancing oncology care significantly.
On June 7, 2022, The Oncology Institute (NASDAQ: TOI) announced its inclusion in the Russell 2000 and Russell 3000 Indexes, effective June 27, following the annual reconstitution. This milestone reflects TOI's growth since going public in November 2021. The Russell indexes, widely utilized by investment managers, encompass 4,000 of the largest US stocks, ranked by market capitalization. Brad Hively, CEO, expressed enthusiasm for educating stakeholders about TOI's innovative oncology care and strategic achievements. Russell indexes manage approximately $12 trillion in assets.
The Oncology Institute (NASDAQ: TOI) is enhancing community cancer care in Austin, Texas, with two new clinics that opened on May 31, 2022. These facilities focus on comprehensive medical oncology services, including private exam rooms, infusion spaces, and access to clinical trials. The organization emphasizes value-based oncology care, targeting better patient outcomes and reduced financial burdens. TOI aims to disrupt the $200B industry by providing innovative treatment models while committing to patient satisfaction and community support.
The Oncology Institute, Inc. (NASDAQ: TOI) announced CEO Brad Hively's participation in two upcoming investor conferences. The first is the UBS Healthcare Conference on May 24, 2022, at 10:00 AM ET in New York, followed by the Jefferies Healthcare Conference on June 8, 2022, at 4:30 PM ET, also in New York. Interested parties can access live webcasts via the Investor Relations section of their website. Founded in 2007, TOI offers specialized, value-based cancer care to approximately 1.5 million patients across over 50 clinic locations.
The Oncology Institute, Inc. (NASDAQ: TOI) reported Q1 2022 revenue of $55 million, a 14% increase year-over-year, driven by expansion into new markets and value-based partnerships. Patient Services revenue rose 18.3% to $35 million. Gross profit increased by 20.8% to $12 million, supported by improved cost management. However, SG&A expenses surged to $30 million, up from $11 million, impacting adjusted EBITDA, which stood at $(5) million. TOI maintains its 2022 revenue guidance of $270 to $310 million, reflecting a growth of 33% to 53% over 2021.
The Oncology Institute of Hope and Innovation (TOI) has acquired Women’s Cancer Care, expanding its services into California’s Central Valley. This clinic, established in 2001, is the only facility between San Francisco and Los Angeles specializing in breast and gynecologic oncology. The partnership aims to enhance medical resources and provide advanced care solutions to women in the region. TOI now employs over 80 clinicians and expands its presence with a team of more than 30 in Fresno, enhancing its commitment to value-based cancer care.
The Oncology Institute (TOI) will announce its Q1 2022 financial results on May 11, 2022, after market close, followed by a conference call at 5:00 p.m. ET. Investors can access the call by phone or via a webcast on TOI's Investor Relations website. TOI, established in 2007, focuses on value-based cancer care, serving approximately 1.6 million patients with a team of over 80 clinicians across 50 locations. For more details about the upcoming earnings report and the company's services, visit their official website.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) announced substantial achievements in the latest Oncology Care Model (OCM) performance period, saving Medicare nearly $9.5M since 2016 and exceeding target savings by $5.3M. The value-based oncology group showcased above-average quality performance, equating to savings of nearly $4,000 per patient episode. With over 80 employed clinicians and expanding services, TOI emphasizes better oncological outcomes while reducing costs for cancer patients across the U.S.
The Oncology Institute of Hope and Innovation (TOI) has appointed Mihir Shah as its new chief financial officer, effective immediately. With 15 years of experience in healthcare finance, Shah has previously served in CFO roles at organizations like Commonwealth Care Alliance and Apollo Medical Holdings. He will oversee critical functions such as Accounting, Finance, and Investor Relations, aiding TOI's strategic growth. Shah takes over from Scott Dalgleish, who will assist during the transition. TOI aims to enhance oncology care through its extensive services, benefiting around 1.6 million patients.